Constellation Energy Commences Operations at Pin Oak Facility Expanding Power Generation Portfolio Morgan Stanley Maintains Bullish Stance on NextEra Energy Despite Price Target Reduction Trump Seeks Supreme Court Intervention to Delay TikTok Ban AnheuserBusch InBev Shares Dip as Quarterly Sales Fall Short of Analyst Expectations Stellantis Turnaround Prediction Market Regulation Oura IPO Key Morning Market Developments MegaCap Tech Stock Launches RedditStyle App Analysts Eye 35 Potential Upside HNRG Q1 2026 Earnings WiderThanExpected Loss Amid Challenging Coal Market NRSN Q2 2025 Earnings Narrower Loss Surprises Shares Gain on Cost Discipline RWAYI Q1 2026 Earnings EPS Miss Amidst Narrowed Lending Margins REAL Q1 2026 Earnings Narrowing Losses as Consignment Volumes Improve LGIH Q1 2026 Earnings Massive EPS Surprise Driven by Strong Profitability STEL Q1 2026 Earnings EPS Beat Drives Modest Stock Uptick Estrella Immunopharma Warrant ESLAW Surges 1885 to 010 Faces Key Resistance at 011 Activate Energy Acquisition AEAQ Edges Higher Near 999 as Support Holds National Storage Affiliates Trust NSA Rises Slightly as Support Holds Key Levels in Focus BUD Stock Slides 177 Technical Levels and Sector Context Dynamix Corporation ETHM Holds Flat Near 1077 as Support and Resistance Levels Define Trading Range Tech and Healthcare Lead SP 500 Higher Financials Lag ABVX Q4 2025 Earnings WiderThanExpected Loss Highlights ClinicalStage Biotech Challenges BBVA Holds Steady Near 2327 as Support and Resistance Levels Define Trading Range AOS Q1 2026 Earnings EPS Misses Estimates by 107 as Margins Face Headwinds EGO Q1 2026 Earnings Stellar EPS Beat Drives Investor Caution Despite Strong Operational Performance SURG Q4 2025 Earnings Massive EPS Miss Surprises Market MPLX Q1 2026 Earnings EPS Misses Street Estimates as Margins Face Pressure Ares Management ARES Q1 2026 Earnings EPS Misses Street View but Stock Gains on Resilient Business Trends ROCK Q1 2026 Earnings EPS Misses Estimates by Nearly 30 Shares Edge Higher SKYE Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues Development